Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Austria

Research and Innovation Action · Running

DISCOVER-ME Biological evidence and mechanism-based disease classification for the improved diagnosis, prognosis and treatment of ME/CFS (DISCOVER-ME)

Coordinator
Medizinische Universitaet Wien, Austria
Runs
1 July 2026 to 30 June 2030
Status
Running
EU funding
€7.6m
Total cost
€7.6m
Partners
21 organisations in 12 countries
Type
Research and Innovation Action
Grant agreement
101287766

What the project is doing

In the project's own words, from its summary on CORDIS.

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a debilitating multisystem disease affecting up to 1% of the population. It is defined by post-exertional malaise, persistent fatigue, cognitive and neurological symptoms, and autonomic, endocrine, and immune dysfunction. Clinical heterogeneity and the absence of specific diagnostic tests lead to long delays in diagnosis, lack of effective therapies, and a socioeconomic burden exceeding €40 billion annually in Europe.

DISCOVER-ME will deliver the first clinically actionable, biologically validated stratification framework for ME/CFS. Through harmonised clinical phenotyping of 2,000 patients and multi-omics profiling of >900 samples from five European biobanks, the project will identify, validate, and prioritise biomarkers across (epi)genetic, immune, metabolic, neuroendocrine, and vascular domains. This large-scale, reproducible approach overcomes decades of fragmented, underpowered studies that have stalled progress.

Three innovations set DISCOVER-ME apart: (i) a robust biomarker discovery and validation pipeline; (ii) the first systems-level taxonomy of ME/CFS grounded in mechanistic disease drivers and supported by AI-assisted stratification; and (iii) open-access disease maps and digital twin models that combine biological mechanisms with social and economic determinants of health, enabling in silico testing of therapeutic hypotheses.

These outputs will underpin biomarker-guided clinical trials and precision drug repurposing. Patient involvement is embedded throughout—from co-design of phenotyping tools to surveys, stratification frameworks, and policy recommendations—ensuring that lived experience informs all biomedical and computational outputs. By integrating patient, clinical, and biological perspectives, DISCOVER-ME will deliver evidence and tools directly relevant to patients, clinicians, and health systems.

Who is involved

OrganisationCityCountryRole
Medizinische Universitaet WienWienAustriaCoordinator
Delta 4 GmbHWienAustriaParticipant
Fh Joanneum Gesellschaft MbhGrazAustriaParticipant
The University of Western OntarioOntario - LondonCanadaParticipant
Aarhus UniversitetAarhus CDenmarkParticipant
Remedical Me ApsCopenhagenDenmarkParticipant
Idryma Technologias Kai ErevnasIrakleioGreeceParticipant
Fundacion Para El Fomento De La Investigacion Sanitaria Y Biomedica De La Comunitat ValencianaValenciaSpainParticipant
Fundacion Universidad Catolica De Valencia San Vicente MartirValenciaSpainParticipant
Centre National De La Recherche Scientifique CNRSParisFranceParticipant
Universite De ToulouseToulouseFranceThird party
University of GalwayGalwayIrelandParticipant
Landspitali University HospitalReykjavikIcelandParticipant
Stichting Amsterdam UmcAmsterdamNetherlandsParticipant
Institute for Cardiovascular Diseases ""Dedinje""""BelgradeSerbiaParticipant
European Me Alliance EmeaStockholmSwedenParticipant
Uppsala UniversitetUppsalaSwedenParticipant
Cardiff UniversityCardiffUnited KingdomParticipant
Imperial College of Science Technology and MedicineLondonUnited KingdomParticipant
London School of Hygiene and Tropical Medicine Royal CharterLondonUnited KingdomParticipant
Quadram Institute BioscienceNorwichUnited KingdomParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI